EKF Diagnostics announced on Thursday that its subsidiary Renalytix AI has signed an exclusive licence and collaboration agreement with New York's Icahn School of Medicine at Mount Sinai.
Point-of-care business EKF Diagnostics Holdings updated the market on its trading on Thursday, announcing that its second quarter saw a continuation of the "favourable trends" experienced in the first quarter.
Point-of-care business EKF Diagnostics Holdings announced on Monday that trading in the final quarter of the year ended 31 December was "materially better than budget", and that the overall performance for the year will exceed revised market forecasts, which themselves were recently upgraded following the trading update provided on 7 November.
AIM-listed point-of-care business EKF Diagnostics said on Monday that revenues and adjusted earnings for the year to the end of December are likely to be ahead of current market forecasts.
Point-of-care business EKF Diagnostics Holdings announced its unaudited interim results for the six months to 30 June on Monday, ahead of market expectations.
EKF Diagnostics shares rose on Wednesday as Panmure Gordon reiterated a 'buy' rating and target price of 14p after an upbeat trading update.
Harwood Capital, acting as investment manager on behalf of North Atlantic Smaller Companies Investment Trust PLC, picked up another large batch of shares in EKF Diagnostics.
Ron Zwanziger has resigned as non-executive director of EKF Diagnostics with immediate effect.
The AIM-listed point-of-care business EKF Diagnostics Holdings has appointed Christopher Mills as non-executive chairman with immediate effect.
Shares in EKF Diagnostics bounced off their all-time low thanks to a trading update that reiterated full-year profit guidance and emphasised its total focus on point-of-care.
EKF Diagnostics Holdings all but admitted defeat in its experiment with personalised medicine on Wednesday, as it let go of its wholly-owned subsidiary Selah back to the founders.
A clinical study part-funded by EKF Diagnostics has provided encouraging data about its soluble biomarker in predicting the progression of diabetic kidney disease, which could lead to recruitment of more suitable patients for further trials.
EKF Diagnostics, which was recently pressured by its major shareholders into putting its point-of-care business up for sale, has reportedly received offers from two unidentified bidders.
EKF Diagnostics Holdings has agreed a non-binding deal to sell its point-of-care business for $110m (£70m) and assured investors that it expects to hit its full year target despite declining first-half profits.
Shares in medical diagnostic equipment producer EKF Diagnostic tanked on Monday as the group swung to an annual pre-tax loss in 2014 on exceptional costs.
Medical group EKF Diagnostics warned on annual profits after taking a currency hit and saying revenue from newly acquired companies was likely to be lower than expected.
Aberdeen: Goldman Sachs ups target price from 540p to 560pp retaining a buy recommendation.
Medical group EKF Diagnostics says a partnership in which it is involved has made a major step towards detecting cancer in blood.
ASOS: Goldman Sachs reduces target price from 7300p to 6250p, while upgrading to buy.
Balfour Beatty: Jefferies reduces target price from 403p to 233p downgrading to hold. Deutsche Bank cuts target price from 280p to 250p and leaves its hold recommendation unchanged. Numis reduces target price to 260p and retains an add rating.